| Literature DB >> 28376083 |
Amandine Duchesne1, Anne Vaiman1, Johan Castille1, Christian Beauvallet1, Pauline Gaignard2, Sandrine Floriot1, Sabrina Rodriguez1,3, Marthe Vilotte1, Laurent Boulanger4, Bruno Passet1, Olivier Albaric5, François Guillaume1, Abdelhak Boukadiri1, Laurence Richard6, Maud Bertaud1, Edouard Timsit7, Raphaël Guatteo8, Florence Jaffrézic1, Pierre Calvel1, Louise Helary1, Rachid Mahla9, Diane Esquerré10, Christine Péchoux1, Sophie Liuu11, Jean-Michel Vallat6, Didier Boichard1, Abdelhamid Slama2, Jean-Luc Vilotte1.
Abstract
Neuropathies are neurodegenerative diseases affecting humans and other mammals. Many genetic causes have been identified so far, including mutations of genes encoding proteins involved in mitochondrial dynamics. Recently, the "Turning calves syndrome", a novel sensorimotor polyneuropathy was described in the French Rouge-des-Prés cattle breed. In the present study, we determined that this hereditary disease resulted from a single nucleotide substitution in SLC25A46, a gene encoding a protein of the mitochondrial carrier family. This mutation caused an apparent damaging amino-acid substitution. To better understand the function of this protein, we knocked out the Slc25a46 gene in a mouse model. This alteration affected not only the nervous system but also altered general metabolism, resulting in premature mortality. Based on optic microscopy examination, electron microscopy and on biochemical, metabolic and proteomic analyses, we showed that the Slc25a46 disruption caused a fusion/fission imbalance and an abnormal mitochondrial architecture that disturbed mitochondrial metabolism. These data extended the range of phenotypes associated with Slc25a46 dysfunction. Moreover, this Slc25a46 knock-out mouse model should be useful to further elucidate the role of SLC25A46 in mitochondrial dynamics.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28376083 PMCID: PMC5380314 DOI: 10.1371/journal.pgen.1006597
Source DB: PubMed Journal: PLoS Genet ISSN: 1553-7390 Impact factor: 5.917
Variants detected by whole-genome sequencing of four Rouge-des-Prés cattle, including two calves with polyneuropathy.
| Filtering steps | No. polymorphisms |
|---|---|
| Polymorphisms in the 3.1 Mb homozygous interval | 9025 |
| Polymorphisms homozygous in both affected cattle, but absent in WT | 1594 |
| Polymorphisms absent from dbSNP database | 973 |
| Polymorphisms absent from Illumina SNP chip | 678 |
| Non-synonymous coding polymorphisms | 2 |
Information concerning the two candidate causal mutations identified after whole-genome sequencing.
Each polymorphism was mapped on the UMD3.1 assembly of bovine reference genome. Ref. allele, reference allele; alt. allele, alternative allele; Aa subst., amino-acid substitution.
| Position UMD3.1 | Ref. allele | Alt. allele | Gene | Consequence | Aa subst. | Prediction (SIFT) |
|---|---|---|---|---|---|---|
| 7:111552659 | A | G | Nonsynonymous coding | K/R | Tolerated | |
| 7:112337413 | C | T | Nonsynonymous coding | R/C | Damaging |
Biochemical analysis of plasma from WT and homozygous Tg-/- mice (n≥7 for each genotype).
For glucose and bile acids, measures were repeated on another group of mice.
| Parameter | WT | Affected | p-value |
|---|---|---|---|
| 10.67 ± 1.25 | 5.76 ± 2.62 | ||
| 13.02 ± 2.75 | 9.46 ± 2.99 | ||
| Sodium (mmol/L) | 146.67 ± 4.13 | 153 ± 8.28 | |
| 11.68 ± 1.01 | 9.68 ± 1.02 | ||
| Chloride (mmol/L) | 114.33 ± 1.97 | 118.5 ± 8.93 | |
| 2.35 ± 0.10 | 1.91 ± 0.31 | ||
| Phosphorus (mmol/L) | 3.05 ± 0.41 | 3.05 ± 0.43 | |
| Magnesium (mmol/L) | 0.77 ± 0.08 | 0.74 ± 0.05 | |
| Urea (mmol/L) | 7.23 ± 2.07 | 6.81 ± 1.86 | |
| 59.45 ± 8.78 | 18.6 ± 10.88 | ||
| 64.17 ± 17.28 | 120.62 ± 42.34 | ||
| 41.17 ± 2.56 | 39 ± 1.85 | ||
| Albumin (g/L) | 23.73 ± 3.13 | 23.52 ± 1.32 | |
| 0.99 ± 0.19 | 1.7 ± 0.47 | ||
| 2.38 ± 0.93 | 5.19 ± 1.02 | ||
| 3.98 ± 3.09 | 9.86 ± 7.27 | ||
| 3.25 ± 0.19 | 5.85 ± 1.40 | ||
| Triglycerides (mmol/L) | 1.54 ± 0.45 | 1.25 ± 0.40 | |
| Creatinine (μmol/L) | 9.42 ± 1.98 | 8.17 ± 2.04 | |
| Beta hydroxybutyrate ( mmol/L) | 0.29 ± 0.22 | 0.92 ± 0.73 | |
| 171.62 ± 57.50 | 335.75 ± 142.80 | ||
| 58.73 ± 9.80 | 92.23 ± 23.74 | ||
| Alanine amino transferase (Alat; IU/L) | 21.50 ± 8.22 | 20.09 ± 10.37 | |
| Lactate (mmol/L) | 3.40 ± 2.57 | 3.04 ± 2.26 |
* p = 0.05
** p = 0.01
*** p = 0.001, Student test.
MS/MS results (protein extracts from brain tissues).
The MS/MS data were analyzed for three WT and four Tg-/- mice. Downregulated and upregulated proteins were selected based on the adjusted p-value (threshold = 0. 2). Total MS/MS data are provided in .
| Prot ID | Uniprot | Protein | Protein ID | Gene name | Adj p-value | Regulation | Pathway/function |
|---|---|---|---|---|---|---|---|
| a2.a8.a1 | P20029 | 78 kDa glucose-regulated protein | Grp78 | 0,0485458 | Down | Heat shock protein | |
| b63.a1.a1 | Q64521 | Glycerol-3-phosphate dehydrogenase, mitochondrial | Gpdm | 0,0485458 | Down | Fatty acid, triacylglycerol, and ketone body metabolism | |
| b98.a1.a1 | Q91VD9 | NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial | Ndus1 | 0,0485458 | Down | Respiratory electron transport | |
| c554.a1.a1 | P37040 | NADPH—cytochrome P450 reductase | Ncpr | 0,0485458 | Down | ||
| d1032.a1.a1 | Q9CQS4 | Solute carrier family 25 member 46 | S2546 | 0,0485458 | Down | ||
| c211.a1.a1 | Q8BMS1 | Trifunctional enzyme subunit alpha, mitochondrial | Echa | 0,06995003 | Down | Fatty acid metabolism | |
| c200.a1.a1 | Q9CZW5 | Mitochondrial import receptor subunit TOM70 | Tom70 | 0,11460448 | Down | Mitochondrial protein import | |
| a2.b10.a1 | P16627 | Heat shock 70 kDa protein 1-like | Hs71l | 0,12045145 | Down | Heat shock protein | |
| a2.b11.a1 | P17879 | Heat shock 70 kDa protein 1B | Hs71b | 0,12045145 | Down | Heat shock protein | |
| b31.a1.a1 | P17710 | Isoform HK1 of Hexokinase-1 | Hxk1 | 0,12045145 | Down | Glucose transport | |
| c407.a1.a1 | P29341 | Polyadenylate-binding protein 1 | Pabp1 | 0,12045145 | Down | ||
| c176.a1.a1 | Q02248 | Catenin beta-1 | Ctnb1 | 0,13406441 | Down | ||
| b31.a2.a1 | P17710 | Isoform HK1-SB of Hexokinase-1 | Hxk1 | 0,14051012 | Down | Glucose transport | |
| a2.a5.a1 | P63017 | Heat shock cognate 71 kDa protein | Hsp7c | 0,15925716 | Down | Heat shock protein | |
| b52.a1.a1 | Q61301 | Isoform 2 of Catenin alpha-2 | Ctna2 | 0,1764172 | Down | ||
| c521.a1.a1 | P56399 | Ubiquitin carboxyl-terminal hydrolase 5 | Ubp5 | 0,1764172 | Down | ||
| c119.a1.a1 | Q61316 | Heat shock 70 kDa protein 4 | Hsp74 | 0,18162435 | Down | Heat shock protein | |
| c324.a1.a1 | P14824 | Annexin A6 | Anxa6 | 0,19304849 | Down | ||
| c531.a1.a1 | Q8CHT1 | Isoform 2 of Ephexin-1 | Ngef | 0,19304849 | Down | ||
| c337.a1.a1 | Q60598 | Src substrate cortactin | Src8 | 0,19916148 | Down | ||
| c174.a1.a1 | P01942 | Hemoglobin subunit alpha | Hba | 0,0485458 | Up | Heme/oxygen/iron binding | |
| b46.a1.a1 | P02088 | Hemoglobin subunit beta-1 | Hbb1 | 0,06327584 | Up | Heme/oxygen/iron binding | |
| b46.a2.a1 | P02089 | Hemoglobin subunit beta-2 | Hbb2 | 0,08502057 | Up | Heme/oxygen/iron binding | |
| c137.a1.a1 | P63082 | V-type proton ATPase 16 kDa proteolipid subunit | Vatl | 0,09458836 | Up | ||
| c391.a1.a1 | Q9JJV2 | Profilin-2 | Prof2 | 0,14790441 | Up | ||
| c506.a1.a1 | Q8R1Q8 | Cytoplasmic dynein 1 light intermediate chain 1 | Dc1l1 | 0,19304849 | Up |
Comparative description of mammalian cases of SLC25A46 mutations.
The age of onset refers to the onset of neurological symptoms. ND, non-detected; NA, non-analyzed.
| “Turning calves syndrome” [ | Model KO for SLC25A46 | UK family [ | PL family [ | IT family [ | US family [ | Optic atrophy [ | Leigh syndrome [ | ||
|---|---|---|---|---|---|---|---|---|---|
| Bovine | Mouse | Human | Human | Human | Human | Human | Human | ||
| c. 376C>T | Compound c.165_166insC and c.746G>A | c.1005A>T | c.1018C>T | Compound c.882_885dupTTAC and c.998C>T | c.283+3G>T, no wild-type mRNA detected | c.425C > T | |||
| SLC25A46 | p. R126C detected | No protein detected | p.His56fs*94 and p.Gly249Asp | p.Glu335Asp | p.Arg340Cys | p.Asn296fs*297 and p.Pro333Leu | Absence of protein suspected | No protein detected | |
| 1 month | 2 weeks | 5–8 years | 1–2 years | 2 years | Birth | Birth | 4 months | ||
| Unknown (euthanasia around 2–3 months) | 3–4 weeks | No (around 40 ‘s) | No (13 months //11.5 years) | No (51 years) | 15 weeks | 7 days | 14.5 months | ||
| + | + | + | + | + | + | + | |||
| + | + (mild) | + (adulthood) | + | + (young adulthood) | + (birth) | + | + | ||
| ND | ND | + (early) | + (early) | + (early) | + (early) | + | + (early) | ||
| NA | Growth defect,Epilepsy | Slight bilateral deafness | Myopathy with small fibers | Myoclonic jerks | Uncoordina-ted oral phase | ||||
| Numerous aggregated mitochondria | Numerous aggregated mitochondria | NA | Numerous mitochondria | Hyperfilamen-tous | NA | Mitochondrial fragmentation | Hyperfused | ||
| Small and altered mitochondria | Small mitochondria, decrease of cristae junctions, vesicular-like cristae | NA | Normal | NA | NA | NA | Very narrow mitochondria, markedly reduced cristae | ||